SNIPR Biome

SNIPR Biome is a pioneering startup in the field of microbial gene therapy, specifically using CRISPR technology. CRISPR is a tool that allows scientists to edit genes, essentially cutting and pasting DNA to correct genetic defects or to introduce new genes. SNIPR Biome is applying this technology to the microbiome, the community of microbes that live in our bodies, to develop new treatments for serious diseases like inflammatory bowel disease, multi-drug resistant infections, and cancer.

The company was founded in 2017 and has quickly grown to a team of over 40, mostly PhDs. They have raised $50 million in Series A funding, one of the largest rounds in Europe, from four major European funds. This funding is being used to advance their CRISPR-based microbiome drugs to human clinical trials.

SNIPR Biome operates in the biotechnology market, specifically in the area of gene therapy. Their business model revolves around developing and patenting innovative treatments, with 28 patents already granted in the US. They also recently launched a non-profit patent licensing program to enable further research in the field of CRISPR editing in prokaryotes, which are single-celled organisms like bacteria.

The company is based in Copenhagen, Denmark, and is always on the lookout for new talent to join their team. They describe their working environment as fun, fast-paced, collaborative, and outcome-focused.

Keywords: CRISPR, Microbial Gene Therapy, Microbiome, Biotechnology, Gene Editing, Patent Licensing, Clinical Trials, Inflammatory Bowel Disease, Multi-drug Resistant Infections, Cancer.